share_log

B of A Securities Downgrades Fulcrum Therapeutics to Underperform, Lowers Price Target to $2

Benzinga ·  Sep 13 01:55  · Ratings

B of A Securities analyst Tazeen Ahmad downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Underperform and lowers the price target from $10 to $2.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment